Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon Graham

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2024
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate modelAlex Ocampo, Farhad Hatami, Jelena Čuklina, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Neurology and Therapy|July 14, 2023
The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis TreatmentStephen L Hauser, Ludwig Kappos, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2024
Prognostic factors for worsening and improvement in multiple sclerosis using a multistate modelAlex Ocampo, Farhad Hatami, Jelena Čuklina, et al.
Nature Medicine|August 20, 2025
AI-driven reclassification of multiple sclerosis progressionHabib Ganjgahi, Dieter A Häring, Piet Aarden, et al.
Pageof 3